GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 56.72B |
| Revenue (ttm) | 31.63B |
| Net Income (ttm) | 3.42B |
| Shares Out | 4.01B |
| EPS (ttm) | 0.83 |
| PE Ratio | 17.13 |
| Forward PE | 8.25 |
| Dividend | 0.61 (4.25%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 4,704,177 |
| Average Volume | 7,954,067 |
| Open | 1,415.50 |
| Previous Close | 1,435.00 |
| Day's Range | 1,402.00 - 1,417.00 |
| 52-Week Range | 1,242.50 - 1,678.68 |
| Beta | 0.27 |
| RSI | 52.20 |
| Earnings Date | Jul 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P...
GSK bid to expand Blujepa label for gonorrhea granted FDA priority review
GSK's antibiotic drug gepotidacin gets priority review by FDA
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral t...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
Drugmaker GSK lands £372m in Covid jab pact
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
Trump demands U.S. drug price cuts, pharma shares slump
AstraZeneca Plc fell as much as 4.2%, and GSK Plc dropped 2.1%
GSK declares $0.4206 dividend
Trump threatens NHS with higher drug prices
The US president has told GSK and AstraZeneca to ‘negotiate harder with foreign freeloading nations’
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P...
How Is The Market Feeling About GSK?
GSK's (NYSE: GSK) short percent of float has fallen 27.17% since its last report. The company recently reported that it has 13.51 million shares sold short , which is 0.67% of all regular shares that...
GSK plc (GSK) Q2 2025 Earnings Call Transcript
GSK plc (NYSE:GSK) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley ...
GSK CEO: Innovation is the secret to bringing down cost of overall healthcare
Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation pipeline, the potential impact of tariffs on pharmaceuticals, and much more.